CN112250588B - L-carnitine ionic liquid and preparation method and application thereof - Google Patents
L-carnitine ionic liquid and preparation method and application thereof Download PDFInfo
- Publication number
- CN112250588B CN112250588B CN202011228583.5A CN202011228583A CN112250588B CN 112250588 B CN112250588 B CN 112250588B CN 202011228583 A CN202011228583 A CN 202011228583A CN 112250588 B CN112250588 B CN 112250588B
- Authority
- CN
- China
- Prior art keywords
- carnitine
- ionic liquid
- hours
- preparation
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 128
- 239000002608 ionic liquid Substances 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- ZHYZQXUYZJNEHD-VQHVLOKHSA-N geranic acid Chemical compound CC(C)=CCC\C(C)=C\C(O)=O ZHYZQXUYZJNEHD-VQHVLOKHSA-N 0.000 claims abstract description 31
- 229930008392 geranic acid Natural products 0.000 claims abstract description 31
- ZHYZQXUYZJNEHD-UHFFFAOYSA-N trans-geranic acid Natural products CC(C)=CCCC(C)=CC(O)=O ZHYZQXUYZJNEHD-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 22
- 229960001518 levocarnitine Drugs 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 18
- 238000006011 modification reaction Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 238000001291 vacuum drying Methods 0.000 abstract description 11
- 239000002243 precursor Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 150000001450 anions Chemical class 0.000 abstract description 4
- 150000001768 cations Chemical class 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 108090000854 Oxidoreductases Proteins 0.000 abstract description 3
- 102000004316 Oxidoreductases Human genes 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 229940014144 folate Drugs 0.000 abstract description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract description 3
- 235000019152 folic acid Nutrition 0.000 abstract description 3
- 239000011724 folic acid Substances 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 239000011829 room temperature ionic liquid solvent Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 description 12
- 239000012300 argon atmosphere Substances 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 8
- 239000000178 monomer Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- -1 l-carnitine nitrogen Chemical compound 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000134874 Geraniales Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Abstract
The invention provides an L-carnitine ionic liquid, and a preparation method and application thereof. The L-carnitine is taken as a cation precursor, the geranic acid is taken as an anion precursor, the L-carnitine ionic liquid is synthesized through an ionization modification reaction, and the L-carnitine ionic liquid with higher purity is obtained through vacuum drying after the reaction is finished. The L-carnitine folate is room temperature ionic liquid, has good solubility, absorptivity, stability and bioavailability, and is proved by tests to have non-toxic and excellent transdermal absorption effect, so that the activity of the fatty acid oxidase is enhanced, the fat oxidation is promoted, and the weight and the blood fat level are reduced. The prepared L-carnitine ionic liquid has excellent transdermal effect, so that the L-carnitine ionic liquid can be used as a cosmetic raw material to be applied to a cosmetic formula and can also be used for oral delivery of medicines.
Description
Technical Field
The invention belongs to the technical field of ionic liquid, and particularly relates to L-carnitine ionic liquid as well as a preparation method and application thereof.
Background
L-carnitine, also known as L-carnitine or carnitine, is a compound closely related to fat metabolism in the body, and has the main physiological function of serving as a fat carrier, transporting long-chain fatty acids from mitochondria to the inside of a membrane in the form of fatty acyl carnitine, and promoting fat oxidative decomposition.
L-carnitine has become a popular safe diet food in recent years. But the existing L-carnitine monomer has the defect of low utilization rate in the application process.
Therefore, how to improve the utilization rate of the L-carnitine is an urgent problem to be solved.
Disclosure of Invention
The invention provides an L-carnitine ionic liquid, and a preparation method and application thereof, and aims to solve the technical problem of low utilization rate of an L-carnitine monomer in the application process in the prior art to a certain extent.
The technical scheme for solving the technical problems is as follows:
in a first aspect, an l-carnitine ionic liquid is provided, and the structural formula of the l-carnitine ionic liquid is as follows:
the second aspect provides a preparation method of L-carnitine ionic liquid, which comprises the following steps:
mixing L-carnitine and geranic acid according to a molar ratio of 1-8; reacting at 20-80 deg.C to obtain L-carnitine ionic liquid.
Optionally, the preparation method of the l-carnitine ionic liquid further comprises the following steps:
and drying the L-carnitine ionic liquid under a vacuum condition.
Optionally, the preparation method of the L-carnitine ionic liquid, wherein the drying time for drying under vacuum condition is 24-48 hours.
Optionally, the preparation method of the L-carnitine ionic liquid comprises the step of reacting at 20-80 ℃, wherein the reaction time is 4-24 hours.
Optionally, the preparation method of the l-carnitine ionic liquid comprises the following steps of mixing the l-carnitine and the geranic acid according to a molar ratio of 1.
Optionally, the preparation method of the L-carnitine ionic liquid comprises the step of reacting at 30-70 ℃ to obtain the L-carnitine ionic liquid.
In a third aspect, the invention provides an L-carnitine ionic liquid, which is prepared by the preparation method.
In a fourth aspect, the present invention provides an L-carnitine ionic liquid as described above, for use as a cosmetic formulation material.
In a fourth aspect, the invention provides an L-carnitine ionic liquid as described above, and an application of the L-carnitine ionic liquid as a drug delivery carrier material.
The preparation method has the beneficial effects that the L-carnitine is used as a cation precursor, the geranic acid is used as an anion precursor, the L-carnitine and geranic acid ionic liquid is synthesized through an ionization modification reaction, and the L-carnitine and geranic acid ionic liquid is directly obtained without purification after the reaction is finished. The L-carnitine ionic liquid is room-temperature ionic liquid, and has better solubility and absorptivity compared with solid L-carnitine monomers and salts, so that the utilization rate of the L-carnitine in application can be improved.
Drawings
FIG. 1 is nuclear magnetic hydrogen spectrum diagram of L-carnitine ionic liquid provided by the embodiment of the invention;
FIG. 2 is a nuclear magnetic carbon spectrum of an L-carnitine ionic liquid provided by an embodiment of the present invention;
fig. 3 is a two-dimensional nuclear magnetic hydrogen spectrum diagram of the l-carnitine ionic liquid provided by the embodiment of the invention;
fig. 4 is a cytotoxicity spectrum of l-carnitine ionic liquid provided by the embodiment of the present invention;
fig. 5 is a spectrum of transdermal delivery of l-carnitine ionic liquid provided by an embodiment of the present invention;
fig. 6 is a spectrogram of the l-carnitine ionic liquid for reducing fat provided by the embodiment of the present invention.
Detailed Description
To facilitate an understanding of the invention, the invention will now be described more fully with reference to the accompanying drawings. Preferred embodiments of the present invention are shown in the drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The inventor finds that the existing weight-losing products and health-care products developed based on exogenous L-carnitine have the problems of single activity, low absorption and utilization rate by human bodies, high price and the like in the application process.
Based on this, the present invention provides a solution to the above technical problem, and the details thereof will be explained in the following embodiments.
The embodiment provides an L-carnitine ionic liquid, and a preparation method thereof comprises the following steps:
mixing L-carnitine and geranic acid according to a molar ratio of 1-8; reacting at 20-80 deg.C to obtain L-carnitine ionic liquid.
Specifically, under the inert gas atmosphere, adding the L-carnitine and the geranic acid into a reaction vessel according to the molar ratio of 1-8, stirring to uniformly mix the L-carnitine and the geranic acid to obtain a mixture, heating the mixture, and performing an ionization modification reaction on the mixture at the temperature of 20-80 ℃ to obtain the L-carnitine ionic liquid. Wherein, the structural formula of the L-carnitine ionic liquid is as follows:
in the embodiment, the L-carnitine is used as a cation precursor, the geranic acid is used as an anion precursor, the L-carnitine ionic liquid is synthesized through an ionization modification reaction, and separation and purification of a product are not needed after the reaction is finished. The L-carnitine folate is liquid, and has better fluidity, solubility, absorbability, stability and bioavailability compared with solid L-carnitine monomers, and tests show that the L-carnitine ionic liquid has a non-toxic and excellent transdermal absorption effect; meanwhile, the activity of the fatty acid oxidase can be enhanced, the fat oxidation is promoted, and the weight and the blood fat level are reduced. In addition, the L-carnitine ionic liquid has various functions of L-carnitine and geranic acid in efficacy and has double enhancement effects. In addition, compared with other ionic liquids, the method for successfully preparing the L-carnitine ionic liquid is simple and easy to understand, easy to operate, free of any solvent, easy to implement by using instruments and reaction conditions, and concise in synthesis steps. Compared with the L-carnitine monomer, the L-carnitine and geranic acid ionic liquid prepared by the embodiment has high bioavailability and good transdermal absorption effect, and can meet the requirements of general research.
In one embodiment of this example, the geranic acid is a natural product from plants such as cardamom, lemongrass, etc., used as a widely used food additive, and has been considered safe; in addition, geranic acid can dredge the skin's channels, allowing ionic liquids to penetrate the stratum corneum barrier of the skin. Therefore, the L-carnitine ionic liquid can be used for oral delivery of medicines.
In one embodiment of this embodiment, the molar ratio of geranic acid to l-carnitine can be 1:1,1:2,1:3,1:4,1:5,1:6,1:7,1:8,2:1. the L-carnitine ionic liquids obtained by different molar ratios show different ionic-ionic and intra-ionic interactions. As shown in fig. 3, the main interaction between ionic liquids is the interaction between a proton attached to the sp3 carbon (including terminal and internal methyl groups) and the methyl group on the l-carnitine nitrogen. In a molar ratio of 1:1, weak interaction between hydroxyl protons in L-carnitine and internal protonic acid in geranic acid; when the molar ratio is 2:1, methyl groups connected with nitrogen dominate the interaction, but the excessive amount of choline and the existence of relatively small geranial acid molecules lead to the weakening of the intermolecular interaction; in addition, when the molar ratio is 1:2,1:4-1: at 8, the weak interaction between the terminal and internal protons of l-carnitine and geranic acid is achieved by a small amount of acid in the l-carnitine molecule. Two-dimensional nuclear magnetic experiments show that the molar ratios of the different ratios are different at the molecular level and have different microscopic interactions. The composition of ionic liquids is important for drug delivery because the presence of different microscopic interactions may cause each variant to behave differently in a biological environment. For example, an increased geranic acid content increases the hydrophobicity of the solvent, allowing the hydrophobic molecules to dissolve; the higher content of the L-carnitine increases the hydrophilicity of the ionic liquid and dissolves more hydrophilic molecules. The extent of interaction of each of the different molar ratios of ions will also affect their interaction with the drug and the skin.
In one embodiment of this embodiment, the temperature of the ionization modification reaction may be 20 ℃ to 30 ℃,30 ℃ to 40 ℃,40 ℃ to 50 ℃,50 ℃ to 60 ℃,60 ℃ to 70 ℃,70 ℃ to 80 ℃, and the reaction rate is faster at the above reaction temperature.
In one embodiment of this embodiment, the time for the ionization modification reaction may be 4 hours to 8 hours, 8 hours to 12 hours, 12 hours to 16 hours, 16 hours to 20 hours, 20 hours to 24 hours, and the reaction time is sufficient to complete the reaction.
In one embodiment of this example, the obtained l-carnitine ionic liquid is vacuum dried for 24 hours 28 hours, 28 hours 32 hours, 32 hours 36 hours, 36 hours 40 hours, 40 hours 44 hours, 44 hours 48 hours, so as to prevent the ionic liquid from deteriorating.
The present invention provides an L-carnitine ionic liquid, and a preparation method and application thereof, which are further explained by the following specific examples.
Example 1
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.01mol of geranic acid is dropwise added into the reactor with the L-carnitine and stirred to be uniformly mixed, and the mixture is heated to 20 ℃ for ionization modification reaction for 4 hours;
and after the reaction is finished, drying the mixture in a vacuum drying oven for 24 hours to obtain pure L-carnitine ionic liquid.
As shown in fig. 1, the nuclear magnetic resonance hydrogen spectrum data of the l-carnitine acid ionic liquid prepared in this example is: 1H NMR (400mhz, dmso-d 6) δ =10.73 (s, 1H), 5.59 (s, 1H), 5.11 (m, 1H), 3.12 (d, 4H), 2.07 (d, 7H), 1.63 (t, 9H); as shown in fig. 2, the nuclear magnetic carbon spectrum data of the obtained l-carnitine ionic liquid is as follows: 13C NMR (400MHz, DMSO-d 6) delta =173.96,173.24,173.06,168.15,167.69,158.18,157.56,131.84,131.61,129.40,126.39,124.20,123.63,117.78,40.56,39.71,27.13,26.79,25.73,18.40,17.75. The melting point of the L-carnitine and geranic acid ionic liquid prepared by the embodiment is 163-208 ℃.
Example 2
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.02mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 30 ℃ for ionization modification reaction for 8 hours;
after the reaction is finished, drying the mixture in a vacuum drying oven for 28 hours to obtain pure L-carnitine ionic liquid.
Example 3
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.03mol of geranic acid is dropwise added into the reactor with the L-carnitine and stirred to be uniformly mixed, the mixture is heated to 40 ℃, and the ionization modification reaction is carried out for 12 hours;
after the reaction is finished, drying the mixture in a vacuum drying oven for 32 hours to obtain pure L-carnitine ionic liquid.
As shown in fig. 3, the two-dimensional nuclear magnetic spectrum of the l-carnitine-geranic acid ionic liquid prepared in this example shows that the molar ratio is 1:3, the main interaction between ionic liquids is the interaction between the proton attached to the sp3 carbon (including the terminal and internal methyl groups) and the methyl group on the l-carnitine nitrogen.
Example 4
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.04mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 50 ℃ for ionization modification reaction for 16 hours;
after the reaction is finished, drying for 36 hours in a vacuum drying oven to obtain pure L-carnitine ionic liquid.
Example 5
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.05mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 60 ℃ to be subjected to ionization modification reaction for 18 hours;
and after the reaction is finished, drying the mixture in a vacuum drying oven for 38 hours to obtain pure L-carnitine ionic liquid.
Example 6
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.06mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 70 ℃ to carry out ionization modification reaction for 20 hours;
after the reaction is finished, drying for 36 hours in a vacuum drying oven to obtain pure L-carnitine ionic liquid.
Example 7
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.07mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 70 ℃ to carry out ionization modification reaction for 22 hours;
and after the reaction is finished, drying the mixture in a vacuum drying oven for 38 hours to obtain pure L-carnitine ionic liquid.
Example 8
Under the argon atmosphere, 0.01mol of L-carnitine is added into a reactor, then 0.08mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 60 ℃ for ionization modification reaction for 20 hours;
after the reaction is finished, the L-carnitine ionic liquid is dried in a vacuum drying oven for 40 hours to obtain pure L-carnitine ionic liquid.
Example 9
Under the argon atmosphere, 0.02mol of L-carnitine is added into a reactor, then 0.01mol of geranic acid is added into the reactor containing the L-carnitine drop by drop and stirred to be uniformly mixed, and the mixture is heated to 80 ℃ to carry out ionization modification reaction for 24 hours;
and after the reaction is finished, drying the mixture in a vacuum drying oven for 48 hours to obtain pure L-carnitine ionic liquid.
The experiment verification of the L-carnitine ionic liquid prepared in the above examples 1 to 9 is carried out, and the experiment result is as follows:
as shown in fig. 4, the survival rate of 4T1 breast cancer cells by the l-carnitine and geranic acid ionic liquids prepared in this example with different molar ratios is greater than 95%, which indicates that the prepared ionic liquids are non-toxic and have better biocompatibility.
As shown in fig. 5, a molar ratio of 1: the accumulative transdermal amount of the L-carnitine ionic liquid is improved by about 2.9 times compared with that of a single L-carnitine aqueous solution, which shows that the prepared ionic liquid can enhance the transdermal absorption effect. In addition, it can also enhance the activity of fatty acid oxidase, promote fat oxidation, and reduce body weight and blood lipid level.
As shown in fig. 6, a molar ratio of 1: compared with the control group (single L-carnitine aqueous solution), the L-carnitine ionic liquid of the invention has obvious statistical significance in that the levels of triglyceride, low-density lipoprotein cholesterol and total cholesterol in serum are obviously reduced (P is less than 0.05), and the level of high-density lipoprotein cholesterol is increased (P is less than 0.05). Thus. The prepared L-carnitine ionic liquid has better lipid-lowering and weight-losing effects than L-carnitine monomers.
In conclusion, the invention provides an L-carnitine ionic liquid, and a preparation method and application thereof. The L-carnitine is taken as a cation precursor, the geranic acid is taken as an anion precursor, the L-carnitine ionic liquid is synthesized through an ionization modification reaction, and the L-carnitine ionic liquid with higher purity is obtained through vacuum drying after the reaction is finished. The L-carnitine folate is room-temperature ionic liquid, has good solubility, absorptivity, stability and bioavailability, and is proved to have non-toxic and excellent transdermal absorption effect by tests. The prepared L-carnitine ionic liquid has excellent transdermal effect, so that the L-carnitine ionic liquid can be used as a cosmetic raw material to be applied to a cosmetic formula and can also be used for oral delivery of medicines.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (5)
1. An L-carnitine ionic liquid and a preparation method thereof, comprising the following steps:
mixing L-carnitine and geranic acid according to a molar ratio of 1; reacting for 12 hours at the temperature of 40 ℃ to obtain the L-carnitine ionic liquid.
2. The l-carnitine ionic liquid of claim 1 further comprising the steps of:
and drying the L-carnitine ionic liquid under a vacuum condition.
3. The L-carnitine ionic liquid of claim 2 wherein the drying time under vacuum is from 24 to 48 hours.
4. Use of the L-carnitine ionic liquid of claim 1 in the preparation of a cosmetic formulation.
5. Use of the l-carnitine ionic liquid of claim 1 in the preparation of a delivery vehicle material for a drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011228583.5A CN112250588B (en) | 2020-11-06 | 2020-11-06 | L-carnitine ionic liquid and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011228583.5A CN112250588B (en) | 2020-11-06 | 2020-11-06 | L-carnitine ionic liquid and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112250588A CN112250588A (en) | 2021-01-22 |
| CN112250588B true CN112250588B (en) | 2023-03-31 |
Family
ID=74265237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011228583.5A Active CN112250588B (en) | 2020-11-06 | 2020-11-06 | L-carnitine ionic liquid and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112250588B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042007B (en) * | 2021-11-22 | 2023-01-06 | 广东丸美生物技术股份有限公司 | L-carnitine-based blue copper peptide ionic liquid and preparation method and application thereof |
| CN115057789B (en) * | 2022-06-30 | 2024-04-02 | 中科萱嘉医养(珠海)健康科技有限公司 | L-carnitine ionic liquid and preparation method and application thereof |
| CN115317398B (en) * | 2022-07-26 | 2023-09-19 | 广州樊文花化妆品有限公司 | Ionic liquid collagen preparation and preparation method and application thereof |
| CN115192472B (en) * | 2022-07-28 | 2023-04-14 | 广州樊文花化妆品有限公司 | Whitening essence containing ionic liquid humanized type III collagen and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108383741A (en) * | 2018-03-16 | 2018-08-10 | 开原亨泰化工有限公司 | It is a kind of to prepare new method of the l-cn at salt |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1274156B (en) * | 1994-09-08 | 1997-07-15 | Avantgarde Spa | "L-CARNITINE SALT AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT FOR THE TREATMENT OF SKIN DISEASES" |
| TR199802492T2 (en) * | 1996-05-31 | 1999-02-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Stable non-hygroscopic salts of L(-) carnitine and the alkanol L(-) carnitine, a process for their preparation and solid, oral intake containing such salts possible compounds. |
| DK1218001T3 (en) * | 1999-09-03 | 2009-04-14 | Sigma Tau Healthscience Spa | Ultrafine L-Carnitine, Methods of Preparation thereof, Compositions Containing It and Methods of Use thereof |
| TW200600092A (en) * | 2004-05-31 | 2006-01-01 | Showa Denko Kk | Topical slimming preparation and a cosmetic containing a carnitine derivative |
| EP1928402B1 (en) * | 2005-09-30 | 2014-03-12 | Showa Denko K.K. | Carnitine derivative, salt thereof, external skin preparation and cosmetic preparation |
| CN101407472B (en) * | 2008-11-21 | 2013-04-17 | 辽宁科硕营养科技有限公司 | L-carnitine dodecyl sulphonate, and preparation method and use thereof |
| CN102018655B (en) * | 2009-09-17 | 2014-04-23 | 苏州纳通生物纳米技术有限公司 | Transdermal medicament delivery combined preparation |
| CN102911068A (en) * | 2011-08-04 | 2013-02-06 | 广州市奥海生物科技有限公司 | L-carnitine L-malate, and preparation method and application thereof |
| CN103664667A (en) * | 2013-12-16 | 2014-03-26 | 天津天成制药有限公司 | Preparation method for acetyl-L-carnitine nitrate |
| CN108079896A (en) * | 2018-02-07 | 2018-05-29 | 广州中健健康科技有限公司 | It is a kind of using biology base ionic liquid by the method for water oil body electropolymerization |
| JP2022527825A (en) * | 2019-04-03 | 2022-06-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Ionic liquids for drug delivery |
| CN110294683A (en) * | 2019-05-20 | 2019-10-01 | 深圳市萱嘉生物科技有限公司 | A kind of glycine betaine phenolic acid ion salt and the preparation method and application thereof technical field |
| CN110251567A (en) * | 2019-07-15 | 2019-09-20 | 深圳市萱嘉生物科技有限公司 | A kind of L-carnitine eutectic solvent and its application |
-
2020
- 2020-11-06 CN CN202011228583.5A patent/CN112250588B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108383741A (en) * | 2018-03-16 | 2018-08-10 | 开原亨泰化工有限公司 | It is a kind of to prepare new method of the l-cn at salt |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112250588A (en) | 2021-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112250588B (en) | L-carnitine ionic liquid and preparation method and application thereof | |
| EP2824157B1 (en) | Novel sugar-derived gelling agent | |
| CN102614091B (en) | Resveratrol nanostructured lipid carrier and preparation method thereof | |
| CN104434791B (en) | A kind of preparation of modified bletilla polysaccharide derivates nanometer carrier and application technology | |
| US11155674B2 (en) | Polymerizable sulfonamide compounds and polymers thereof | |
| CN112370423A (en) | L-carnitine-based emulsion, preparation method and medicine | |
| CN114831957B (en) | Diglyceride microcapsule prepared by Maillard reaction product and preparation method thereof | |
| US20230348361A1 (en) | Ionizable lipid compounds | |
| CN103554296B (en) | A kind of linolic acid modified glucan and prepare the method for polymeric liposome | |
| CN103006553A (en) | Luteolin solution composition | |
| CN111265482B (en) | Glycyrrhetinic acid and/or folic acid ligand modified cantharidin solid lipid nanoparticle and preparation method thereof | |
| CN105147596B (en) | Water-soluble supermolecule salicylic acid gel technology | |
| CN112680486A (en) | Preparation method of R-3-hydroxybutyric acid oligomer and salt/ester thereof | |
| CN103319390A (en) | Alprostadil compound and composition thereof | |
| CN114931516B (en) | Emulsion containing nitric oxide liposome and preparation method thereof | |
| CN111617029A (en) | Loxoprofen sodium gel and preparation method thereof | |
| CN210279110U (en) | Micro-reaction equipment | |
| CN102525886A (en) | Diclofenac diethylamine emulgel and preparation method thereof | |
| CN102499943A (en) | Preparation and anti-tumor activity of polymer wrapped heteropoly acid nano hybrid material | |
| CN106167465B (en) | A kind of Edaravone dimer impurity compound and preparation method thereof | |
| CN116919901A (en) | Curcumin-based ionic liquid liposome and preparation method and application thereof | |
| CN111748010B (en) | Methylprednisolone aceponate anhydrous crystal type and composition thereof | |
| CN113679039B (en) | Polyethylene glycol gallate protein carrier synergist and preparation method and application thereof | |
| CN114933554B (en) | Isotevelol-based injectable supermolecular hydrogel and preparation method and application thereof | |
| CN106083634A (en) | A kind of peptide amphiphile molecule and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240115 Address after: No.2 building, Chongwen Park, Nanshan Zhiyuan, no.3370 Liuxian Avenue, Fuguang community, Taoyuan Street, Nanshan District, Shenzhen, Guangdong Patentee after: Shenzhen Shanhai Innovation Technology Co.,Ltd. Address before: 518055 campus of Harbin Institute of technology, Shenzhen University Town, Taoyuan Street, Nanshan District, Shenzhen City, Guangdong Province Patentee before: HARBIN INSTITUTE OF TECHNOLOGY (SHENZHEN) |